arrow
C

Claire F. Friedman

Memorial Sloan Kettering Cancer Center
H指数:29
被引数:4,016

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial

Ifinatamab deruxtecan,一种B7-H3靶向抗体—药物偶联物,在晚期实体瘤患者中的研究(IDeate-PanTumor01):一项1/2期试验的剂量递增结果

2026-03-300
PRE
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer

一项关于尼洛替尼与卵巢癌新诊断患者新辅助及术后化疗联合应用的试点研究

2025-10-310
PRE
Evaluation of toxicity after radical hysterectomy or trachelectomy and postoperative pelvic intensity-modulated radiation therapy with concurrent chemotherapy for cervical cancer

宫颈癌根治性子宫切除术或宫颈切除术及术后同期化疗联合盆腔调强放射治疗的毒性评估

2025-10-090
PRE
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA

使用细胞游离DNA追踪卵巢癌治疗过程中的克隆进化

Nature
IF48.5
2025-10-010
OA
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

正在进行的基因组加倍塑造卵巢癌的进化和免疫力

Nature
IF48.5
2025-07-160
OA
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

循环肿瘤DNA监测和接受阿特珠单抗治疗的转移性实体瘤患者的血液肿瘤突变负荷

2025-05-280
OAAI
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate

晚期卵巢癌患者接受抗FOLR1抗体药物偶联物治疗后的临床结局

2025-04-010
PRE
Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary

口服孕激素拮抗剂onapristone extended-release联合anastrozole治疗孕激素受体阳性的复发性成年型卵巢颗粒细胞瘤的篮子研究

2025-01-010
PRE
Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

I期安全性及有效性研究:brenetafusp(一种PRAME x CD3 ImmTAC T细胞结合剂)在铂耐药卵巢癌(PROC)中的应用

2024-09-010
PRE
A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors

一项LY4170156(一种靶向叶酸受体α(FRα)表达型晚期实体瘤的抗体制剂偶联物)的首次人体I期研究

2024-09-011
PRE
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
2024-04-234
OAAI
HLA genotyping and HLA-based clinical trial matching using MSK-IMPACT, a targeted next-generation sequencing assay
2024-03-220
PRE
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

晚期实体瘤患者的Ifinatamab deruxtecan (i-dxd; DS-7300): I/II期研究的最新临床和生物标志物结果

2023-10-013
PRE
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
2023-06-099
OAAI
Comprehensive analysis of germline drivers in endometrial cancer
2023-02-069
OA
PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: PART 1 RESULTS
2022-12-081
OA